Pulmonary cryptococcus infection after mono-chemotherapy with gemcitabine

Area of Science:

• Oncology
• Infectious Diseases
• Pulmonology

Background:

• Gemcitabine (difluorodeoxycytidine) is a widely used chemotherapeutic agent for various cancers.
• While effective, gemcitabine is generally associated with a low risk of infection.
• It is often chosen over more toxic combination regimens for its favorable toxicity profile.

Observation:

• A patient with advanced bladder carcinoma developed pneumonia after receiving five courses of gemcitabine.
• Diagnostic investigations, including lung biopsy and antigen testing, identified the causative agent as Cryptococcus neoformans.
• The patient's condition improved significantly following the initiation of antifungal treatment.

Findings:

• This case report documents a rare occurrence of Cryptococcus neoformans pneumonia in a patient undergoing gemcitabine monochemotherapy.
• The pulmonary infection was directly linked to the gemcitabine treatment regimen.
• Successful resolution of the infection was achieved with appropriate antifungal therapy.

Implications:

• This case underscores the importance of considering opportunistic infections, even rare ones, in immunocompromised patients undergoing chemotherapy.
• Clinicians should maintain a high index of suspicion for fungal pneumonia in patients receiving gemcitabine, particularly those with advanced malignancies.
• Early diagnosis and prompt antifungal treatment are crucial for managing such rare gemcitabine-associated infections.